Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase 2 Study to Evaluate the Safety and Immunogenicity of an Ad26.ZEBOV Booster Dose in Human Immunodeficiency Virus Positive (HIV+) Adults Previously Vaccinated With the Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen

NCT05064956 is registered in ClinicalTrials.gov with London School of Hygiene and Tropical Medicine as lead sponsor.

NCT NCT05064956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05064956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase 2 Study to Evaluate the Safety and Immunogenicity of an Ad26.ZEBOV Booster Dose in Human Immunodeficiency Virus Positive (HIV+) Adults Previously Vaccinated With the Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen
Lead sponsor
London School of Hygiene and Tropical Medicine
Phase
Phase 2
Overall status
Completed
Start date
October 6, 2021
Completion date
October 24, 2022
Enrollment
26 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ebola, ebola virus disease, hiv